ACE and chronic kidney disease: This contrasts to higher risk populations such as the large inpatient/outpatient cohort described in 2009 by Einhorn et al who associated chronic kidney disease, and ACE-inhibitor use with a hyperkalemic event rate of 3.2% and with excess mortality.5 This underlines the importance of safely identifying ED patients who do not need further evaluation of their pseudohyperkalemia.